All In Biotech

Drug Trial Radar · NCT03991091

Reducing Neonatal Morbidity by Discontinuing Oxytocin During the Active Phase of 1st Stage of Labor

Reducing Neonatal Morbidity by Discontinuing Oxytocin During the Active Phase of 1st Stage of Labor: a Multicenter Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 2,459 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,459

Actual

Start

Jan 17, 2020

Primary completion

Apr 25, 2022

Study completion Apr 25, 2022

Sponsor

Lead sponsor
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France; URC-CIC Paris Descartes Necker Cochin
First posted
Jun 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure the impact of a discontinuous administration of oxytocin during the active phase of the 1st stage of labor on the neonatal morbidity rate. The investigators hypothesize that discontinuation of oxytocin in the active phase of labor (from 6 cm) in women who received oxytocin in the latent phase or for an induction (before 4 cm of dilation) could reduce neonatal morbidity.

Conditions

  • Neonatal Morbidity

Interventions

  • discontinuation of oxytocin administrationDrug

    Discontinuation of oxytocin administration at the beginning of the active phase of the 1st stage of labor, i.e. oxytocin infusion will be stopped beyond a cervical dilatation of 6cm. In the experimental group, oxytocin can be re-started, if necessary, after 2 hours of arrest of labor.

  • continuation of oxytocin administrationDrug

    continuation of oxytocin administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. neonatal morbidity composite measureTime frame: At birth

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • hospital Cochin; port royal Maternity unit

    Paris, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.